Bleeding risk with apixaban and dabigatran similar to aspirin, suggests study Dr. Kamal Kant Kohli19 Feb 2025 8:00 AM ISTA systematic review and meta-analysis estimating the differences in bleeding risks between therapeutic-dose non-vitamin K oral anticoagulants (NOACs)...
NPPA fixes Ceiling Price of Dabigatran capsules Dr. Divya Colin5 July 2023 6:00 PM ISTNew Delhi: Through a recent notification, the National Pharmaceutical Pricing Authority (NPPA) has fixed the ceiling price of the anticoagulant drug...
Apixaban safer than other options for long-term anticoagulation among the elderly with AF Aditi15 April 2023 9:30 AM ISTAccording to an Original Investigation on Cardiology published in JAMA Network Open entitled, "Comparative Effectiveness and Safety of Oral...
Early switch to dabigatran safe for patients with intermediate-risk pulmonary embolism: PEITHO-2 trial Medha Baranwal20 Oct 2021 9:45 AM ISTGermany: An early switch from heparin to dabigatran in patients with intermediate-risk pulmonary embolism is safe and effective, show results from the...
Dabigatran reduces mortality in patients with atrial fibrillation and obesity: Study MD Editorial Team30 Sept 2021 9:00 AM ISTUSA: According to a study conducted by Cheng-Wei Huang and peers, dabigatran was effective in reducing the risk of thromboembolism and mortality in...
Aspirin with DOACs: More risk with same reward, says JAMA study Dr. Kamal Kant Kohli20 April 2021 7:06 AM ISTResearchers have found in an observational study that concomitant use of a direct oral anticoagulant (DOAC) plus aspirin in some cardiovascular...
Dabigatran etexilate as effective as standard of care in acute VTE in children: Lancet Dr Satabdi Saha15 Feb 2021 2:15 PM ISTRecent research findings have suggested that Dabigatran, an oral anticoagulant, was non-inferior to standard of care in terms of efficacy, with...
Dabigatran etexilate useful alternative to standard care for VTE in children: Lancet MD Bureau18 Dec 2020 10:45 AM ISTDirect oral anticoagulants (DOACs) have become the preferred treatment for venous thromboembolism in adults. However, anticoagulant therapy in...
USFDA approves Praxbind, the first reversal agent for the anticoagulant Pradaxa Meghna A Singhania17 Oct 2015 11:13 AM ISTThe U.S. Food and Drug Administration today granted accelerated approval to Praxbind (idarucizumab) for use in patients who are taking the...
